Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
F01-50
- Development stage
- Preclinical
- Lead developer
- Feromics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
F01-50 is a preclinical-stage chimeric antigen receptor (CAR) T-cell therapy being developed by Feromics for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). The candidate utilizes Feromics' proprietary **ID-CAR-T** (Immune-Directed CAR-T) platform, which is designed to enhance the efficacy and persistence of CAR-T cells within the immunosuppressive tumor microenvironment. F01-50 specifically targets **CD19**, a cell surface marker widely expressed on B-cell malignancies. By incorporating specific immune-modulating components into the CAR construct, the therapy aims to overcome common limitations of conventional CAR-T products, such as T-cell exhaustion and poor durability of response in aggressive lymphomas.
- Other names
- F01-50F-01-50F 01-50
02
Targets
Beyond the preview
Go deeper on F01-50.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on F01-50.